

20 April 2022

To: Recipients of M59, 3rd ed.
 From: Jennifer K. Adams, MT(ASCP), MSHA
 Vice President, Standards and Quality
 Subject: Correction

This notice is intended to inform users of a correction made to CLSI document M59, *Epidemiological Cutoff Values for Antifungal Susceptibility Testing*, 3rd ed. The correction is described below and shown as stricken/highlighted text in the table excerpt.

Table 6. Summary of Available Epidemiological Cutoff Values and/or Breakpoints by Fungal Species

The voriconazole listing for *Candida glabrata* is listed incorrectly as having a breakpoint (BP). The listing has been corrected to read “ECV” alone for accuracy.

Table 6. Summary of Available Epidemiological Cutoff Values and/or Breakpoints by Fungal Species

Species	Drugs									
	Amphotericin B	Anidulafungin	Caspofungin	Fluconazole	Flucytosine	Isavuconazole	Itraconazole	Micafungin	Posaconazole	Voriconazole
Yeasts										
<i>Candida glabrata</i>	ECV	BP/ ECV	BP	BP/ ECV	-	-	ECV	BP/ ECV	ECV	BP/ ECV

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI and regret any inconvenience.